MGUS, SMM, and MM Patient Experience With Coronavirus 19 (COVID-19) Survey

Status unconfirmed

Conditions studied: Multiple Myeloma, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Coronavirus

In brief

The purpose of this study is to examine how patients with multiple myeloma (MM) have been impacted by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. The study will use a questionnaire to further understand how patients are being affected and gather information in order to track the long-term effects of the coronavirus. The scope of the questionnaire will include, COVID-19 diagnosis and treatment, changes in myeloma treatment and care, clinical trial familiarity, health and fitness, and quality of life. This questionnaire is a follow-on to the "MM and COVID-19" questionnaire.

Key facts

Study ID

NCT04727294

Run by

HealthTree Foundation

People needed

1500

Starts

2021-01-22

Expected to finish

2021-12-01

Last updated by the study team

2021-08-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult patients (greater than 18 years) diagnosed with MGUS, smoldering myeloma, and multiple myeloma.
• Access to a computer or electronic device with internet access, or phone
• Willing to create a patient profile on the HealthTree Cure Hub For Multiple Myeloma
• Willing to give electronically-signed consent
• Ability to read questions in English

Where it is running

• HealthTree.org (Online) — Lehi, Utah, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.